APPLYING ARTIFICIAL INTELLIGENCE TO MEDICAL IMAGING FOR CARDIOVASCULAR DISEASE DETECTION
Parmida Ghorbanian, PhD Candidate,
University of Western Australia & Advanced Clinical and Translational Cardiovascular Imaging,
Harry Perkins Institute of Medical Research,
Western Australia
RESEARCHER PROFILE
Filmed in Perth, Australia | July 2026
Parmida is a software engineer and biomedical scientist whose research focuses on translating novel medical imaging technologies into clinical practice to improve the diagnosis and management of cardiovascular disease.
Her current work applies advanced deep learning techniques to retinal polarization-sensitive optical coherence tomography (PS-OCT) imaging, aiming to generate clinically meaningful biomarkers and predictions of cardiovascular disease. Parmida’s collaboration partners include Fiona Stanley Hospital in Murdoch, Western Australia.
She is the recipient of the Novel Heart Disease Imaging Through AI HDR Scholarship and has received multiple awards for her research, including the WACRA Heart-to-Vessel Showcase Award, the South Metropolitan Health Service 3-Minute Project Competition, and the Data Institute Postgraduate Student Researcher Pitch Winner award.
Most recently, she was selected as a finalist in the INCITE Awards, Western Australia’s premier technology innovation awards program.
Source: Supplied and adapted
-
Professor Kim Hemsley
RESEARCH IN BRAIN COMPUTER INTERFACE
@ SYNCHRON
MELBOURNE, VICTORIA, AUSTRALIA -
Trials in treating STIs, vaccines and lipid lowering medications
Since joining Paratus Clinical Research in 2022, Dr Pi Lip Seet has served as both Principal Investigator and Sub-Investigator across Phase I–IV industry-sponsored clinical trials. His research experience spans vaccines, immunology, cardiovascular and endocrine disease, respiratory medicine, gastroenterology, pain management, sleep medicine and adult psychiatry. He has been involved in multiple vaccine development programs, including RSV, influenza, COVID-19, herpes zoster and pneumococcal studies.
-
Pancreatic and lung cancers driven by mutations in the cancer gene KRAS
Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors).
